Aerie Pharmaceuticals

Aerie Pharmaceuticals appoints Huan Sheng director of Clinical Research and Drug Safety

Wednesday, February 8, 2017

Aerie Pharmaceuticals, a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, has announced the appointment of Huan Sheng, M.D., Ph.D., as director of Clinical Research and Drug Safety, reporting to Kristine Erickson, O.D., Ph.D., Aerie’s vice president of Clinical Research.

[Read More]

Aerie reports results of phase III trial of rhopressatm for glaucoma

Wednesday, November 2, 2016

Aerie Pharmaceuticals, a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, has reported the successful 90-day topline efficacy results of its Rocket 4 phase III clinical trial of product candidate Rhopressa, a novel once-daily eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The Rocket 4 trial is designed to provide adequate six-month safety data for European regulatory filing purposes. Rocket 4 is not necessary for new drug application (NDA) filing purposes.

[Read More]

Aerie Pharmaceuticals initiates phase IIb study of PG324

Monday, February 3, 2014

Aerie Pharmaceuticals, a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, has dosed the first patients enrolled in the company’s phase IIb study of PG324, a novel, fixed-combination of Aerie’s AR-13324 and latanoprost, a prostaglandin analogue that is the most widely prescribed glaucoma drug. The 28-day, phase IIb clinical trial is expected to enroll approximately 300 patients with glaucoma or ocular hypertension and will compare two concentrations of PG324 to latanoprost and to AR-13324, all dosed once daily. The efficacy endpoint will be superiority of PG324 to each of its components, as measured by the lowering of mean diurnal intraocular pressure (IOP) on day 28 compared to baseline. Topline results of this trial currently are expected in mid-2014.

[Read More]